Skip to content

Evaluation of Coffee Therapy for Improvement of Renal Oxygenation

Coffee, Renal Oxygenation, Blood Flow and Glomerular Filtration Rate in Early Diabetic Kidney Disease.

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03878277
Acronym
COFFEE
Enrollment
10
Registered
2019-03-18
Start date
2019-07-01
Completion date
2021-09-30
Last updated
2022-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Autoimmune, Diabetes Complications, Diabetic Kidney Disease, Diabetic Nephropathies, Juvenile Diabetes, Type1diabetes, Type1 Diabetes Mellitus

Brief summary

Over 1.25 million Americans have Type 1 Diabetes (T1D), increasing risk for early death from cardiovascular disease (CVD). Despite advances in glycemic and blood pressure control, a child diagnosed with T1D is expected to live up to 17 years less than non-diabetic peers. The strongest risk factor for CVD and mortality in T1D is diabetic kidney disease (DKD). Current treatments, such as control of hyperglycemia and hypertension, are beneficial, but only partially protect against DKD. This limited progress may relate to a narrow focus on clinical manifestations of disease, rather than on the initial metabolic derangements underlying the initiation of DKD. Renal hypoxia, stemming from a potential metabolic mismatch between increased renal energy expenditure and impaired substrate utilization, is increasingly proposed as a unifying early pathway in the development of DKD. T1D is impacted by several mechanisms which increase renal adenosine triphosphate (ATP) consumption and decrease ATP generation. Caffeine, a methylxanthine, is known to alter kidney function by several mechanisms including natriuresis, hemodynamics and renin-angiotensin-aldosterone system. In contrast, to other natriuretic agents, caffeine is thought to fully inhibit the local tubuloglomerular feedback (TGF) response to increased distal sodium delivery. This observation has broad-ranging implications as caffeine can reduce renal oxygen (O2) consumption without impairing effective renal plasma flow (ERPF) and glomerular filtration rate (GFR). There are also data suggesting that chemicals in coffee besides caffeine may provide important cardio-renal protection. Yet, there are no data examining the impact of coffee-induced natriuresis on intrarenal hemodynamic function and renal energetics in youth-onset T1D. Our overarching hypothesis in the proposed pilot and feasibility trial is that coffee drinking improves renal oxygenation by reducing renal O2 consumption without impairing GFR and ERPF. To address these hypotheses, we will measure GFR, ERPF, renal perfusion and oxygenation in response to 7 days of cold brew coffee (one Starbucks® Cold brew 325ml bottle daily \[205mg caffeine\]) in an open-label pilot and feasibility trial in 10 adolescents with T1D already enrolled in the CASPER Study (PI: Bjornstad).

Interventions

DRUGStarbucks® Cold brew - 325ml bottle

Starbucks® Cold brew 325ml bottles daily \[205mg caffeine\] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit

Sponsors

Johns Hopkins University
CollaboratorOTHER
University of Colorado, Denver
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to 21 Years
Healthy volunteers
No

Inclusion criteria

* Youth with T1D (antibody +) with \<10 year duration * Age 12-21 years * Weight \>57 lbs and \<350 lbs * BMI \>5th %ile * HbA1c \<12% * Previous exposure to caffeine

Exclusion criteria

* Anemia * Allergy to shellfish or iodine * Severe illness, recent diabetic ketoacidosis (DKA) * Tachyarrhythmias, Attention-deficit/hyperactivity disorder (ADHD), tremors, tics, Tourette's, arrythmias, insomnia, overactive bladder * Estimated Glomerular Filtration Rate (eGFR) \<60 ml/min/1.73 m2 or creatinine \> 1.5 mg/dl or history of albumin-to-creatinine ratio (ACR) \>300 mg/g * MRI Scanning contraindications (claustrophobia, implantable metal devices that are non-MRI compatible, \>350 lbs) * Pregnancy or nursing * (Angiotensin-converting enzyme) ACE inhibitors, angiotensin receptor blockers (ARBs), diuretics, sodium-glucose co-transport (SGLT) 2 or 1 blockers, daily NSAIDs or aspirin, sulfonamides, thiazolsulfone or probenecid, atypical antipsychotics, steroids

Design outcomes

Primary

MeasureTime frameDescription
Renal Oxygenation1 hourMeasured by blood oxygen level dependent (BOLD MRI), before and after Lasix injection;Regions of interest (ROI) analysis for BOLD MRI will be performed on a Leonardo Workstation (Siemens Medical Systems, Germany). Typically, 1 to 3 regions in each, cortex and medulla, per kidney per slice will be defined leading to a total of about 10 ROIs per region (cortex and medulla) per subject. The mean and standard deviation of these 10 measurements will be used a R2\* measurement for the region, for the subject and for that time point. Additionally, two (delta) R2\*s will be calculated as defined below: (delta) R2\*(medulla, furosemide) = R2\* (medulla, pre-furosemide) - R2\* (medulla, post-furosemide); (delta) R2\*(cortex, medulla) = Baseline R2\* (medulla) - Baseline R2\* (cortex).
Renal Perfusion1 hourMeasured by pseudocontinuous arterial spin labeling (pCASL) MRI; ROI analysis will be used to estimate (delta) M (difference in signal intensity between non-selective and selective inversion images). Using the same ROI, M0 will be estimated from the proton density image. T1 measurements from the same ROI will be obtained by fitting the signal intensity vs. inversion time data as described previously (104) using XLFit (ID Business Solutions Ltd., UK) or T1 maps created using MRI Mapper (Beth Israel Deaconess Medical Center, Boston). Partition coefficient will be assumed to be 0.8 ml/gm (105, 106). These values will then be used to estimate regional blood flow.

Secondary

MeasureTime frameDescription
Glomerular Filtration Rate4 hoursMeasured by Iohexol clearance; An intravenous (IV) line was placed, and participants were asked to empty their bladders. Spot plasma and urine samples were collected prior to iohexol infusion. Iohexol was administered through bolus IV injection (5 mL of 300 mg/mL; Omnipaque 300, GE Healthcare). An equilibration period of 120 min was used and blood collections for iohexol plasma disappearance were drawn at +120, +150, +180, +210, +240 min (11). Because the Brøchner-Mortensen equation underestimates high values of GFR, the Jødal-Brøchner-Mortensen equation was used to calculate the GFR (12). We report absolute GFR (mL/min) and RPF (mL/min) in the main analyses because the practice of indexing GFR and RPF for body surface underestimates hyperfiltration and hyperperfusion (14), and body surface area (BSA) calculations introduce noise into the clearance measurements.
Effective Renal Plasma Flow4 hoursMeasured by para-aminohippurate (PAH) clearance; An intravenous (IV) line was placed, and participants were asked to empty their bladders. Spot plasma and urine samples were collected prior PAH infusion. PAH (2 g/10 mL, prepared at the University of Minnesota, with a dose of \[weight in kg\]/75 × 4.2 mL; IND #140129) was given slowly over 5 min followed by a continuous infusion of 8 mL of PAH and 42 mL of normal saline at a rate of 24 mL/h for 2 h. After an equilibration period, blood was drawn at 90 and 120 min, and RPF was calculated as PAH clearance divided by the estimated extraction ratio of PAH, which varies by the level of GFR (13). We report absolute GFR (mL/min) and RPF (mL/min) in the main analyses because the practice of indexing GFR and RPF for body surface underestimates hyperfiltration and hyperperfusion (14), and body surface area (BSA) calculations introduce noise into the clearance measurements.
Tubular Injury Markers4 hoursMeasured by markers of kidney injury in plasma; Cystatin C (mg/L) was measured by immunoturbidimetric method (Kamiya Biomedical) by our Clinical Translational Research Center Core Laboratory.

Countries

United States

Participant flow

Participants by arm

ArmCount
Cold Brew Coffee
6 days of drinking 1 bottle of Starbucks® Cold brew 325ml \[205 mg caffeine\] every morning between 6am-9am. Starbucks® Cold brew - 325ml bottle: Starbucks® Cold brew 325ml bottles daily \[205mg caffeine\] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit
10
Total10

Baseline characteristics

CharacteristicCold Brew Coffee
Age, Continuous18.5 years
STANDARD_DEVIATION 2.6
Race/Ethnicity, Customized
White non-Hispanic
10 Participants
Sex: Female, Male
Female
4 Participants
Sex: Female, Male
Male
6 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 10
other
Total, other adverse events
1 / 10
serious
Total, serious adverse events
0 / 10

Outcome results

Primary

Renal Oxygenation

Measured by blood oxygen level dependent (BOLD MRI), before and after Lasix injection;Regions of interest (ROI) analysis for BOLD MRI will be performed on a Leonardo Workstation (Siemens Medical Systems, Germany). Typically, 1 to 3 regions in each, cortex and medulla, per kidney per slice will be defined leading to a total of about 10 ROIs per region (cortex and medulla) per subject. The mean and standard deviation of these 10 measurements will be used a R2\* measurement for the region, for the subject and for that time point. Additionally, two (delta) R2\*s will be calculated as defined below: (delta) R2\*(medulla, furosemide) = R2\* (medulla, pre-furosemide) - R2\* (medulla, post-furosemide); (delta) R2\*(cortex, medulla) = Baseline R2\* (medulla) - Baseline R2\* (cortex).

Time frame: 1 hour

ArmMeasureGroupValue (MEAN)Dispersion
Cold Brew CoffeeRenal OxygenationBefore cold brew22.4 s^-1Standard Deviation 1.5
Cold Brew CoffeeRenal OxygenationAfter cold brew22.5 s^-1Standard Deviation 2.1
Primary

Renal Perfusion

Measured by pseudocontinuous arterial spin labeling (pCASL) MRI; ROI analysis will be used to estimate (delta) M (difference in signal intensity between non-selective and selective inversion images). Using the same ROI, M0 will be estimated from the proton density image. T1 measurements from the same ROI will be obtained by fitting the signal intensity vs. inversion time data as described previously (104) using XLFit (ID Business Solutions Ltd., UK) or T1 maps created using MRI Mapper (Beth Israel Deaconess Medical Center, Boston). Partition coefficient will be assumed to be 0.8 ml/gm (105, 106). These values will then be used to estimate regional blood flow.

Time frame: 1 hour

ArmMeasureGroupValue (MEAN)Dispersion
Cold Brew CoffeeRenal PerfusionBefore cold brew (Right kidney ASL)3.02 ml/s/100gStandard Deviation 0.67
Cold Brew CoffeeRenal PerfusionAfter cold brew (Right kidney ASL)3.03 ml/s/100gStandard Deviation 0.62
Cold Brew CoffeeRenal PerfusionBefore cold brew (Left kidney ASL)3.15 ml/s/100gStandard Deviation 0.5
Cold Brew CoffeeRenal PerfusionAfter cold brew (Left kidney ASL)3.03 ml/s/100gStandard Deviation 0.72
Secondary

Effective Renal Plasma Flow

Measured by para-aminohippurate (PAH) clearance; An intravenous (IV) line was placed, and participants were asked to empty their bladders. Spot plasma and urine samples were collected prior PAH infusion. PAH (2 g/10 mL, prepared at the University of Minnesota, with a dose of \[weight in kg\]/75 × 4.2 mL; IND #140129) was given slowly over 5 min followed by a continuous infusion of 8 mL of PAH and 42 mL of normal saline at a rate of 24 mL/h for 2 h. After an equilibration period, blood was drawn at 90 and 120 min, and RPF was calculated as PAH clearance divided by the estimated extraction ratio of PAH, which varies by the level of GFR (13). We report absolute GFR (mL/min) and RPF (mL/min) in the main analyses because the practice of indexing GFR and RPF for body surface underestimates hyperfiltration and hyperperfusion (14), and body surface area (BSA) calculations introduce noise into the clearance measurements.

Time frame: 4 hours

ArmMeasureGroupValue (MEAN)Dispersion
Cold Brew CoffeeEffective Renal Plasma FlowBefore cold brew13.08 ml/sStandard Deviation 1.58
Cold Brew CoffeeEffective Renal Plasma FlowAfter cold brew13.02 ml/sStandard Deviation 0.67
Secondary

Glomerular Filtration Rate

Measured by Iohexol clearance; An intravenous (IV) line was placed, and participants were asked to empty their bladders. Spot plasma and urine samples were collected prior to iohexol infusion. Iohexol was administered through bolus IV injection (5 mL of 300 mg/mL; Omnipaque 300, GE Healthcare). An equilibration period of 120 min was used and blood collections for iohexol plasma disappearance were drawn at +120, +150, +180, +210, +240 min (11). Because the Brøchner-Mortensen equation underestimates high values of GFR, the Jødal-Brøchner-Mortensen equation was used to calculate the GFR (12). We report absolute GFR (mL/min) and RPF (mL/min) in the main analyses because the practice of indexing GFR and RPF for body surface underestimates hyperfiltration and hyperperfusion (14), and body surface area (BSA) calculations introduce noise into the clearance measurements.

Time frame: 4 hours

ArmMeasureGroupValue (MEAN)Dispersion
Cold Brew CoffeeGlomerular Filtration RateBefore cold brew3.25 ml/sStandard Deviation 0.47
Cold Brew CoffeeGlomerular Filtration RateAfter cold brew3.27 ml/sStandard Deviation 0.8
Secondary

Tubular Injury Markers

Measured by markers of kidney injury in plasma; Cystatin C (mg/L) was measured by immunoturbidimetric method (Kamiya Biomedical) by our Clinical Translational Research Center Core Laboratory.

Time frame: 4 hours

ArmMeasureGroupValue (MEAN)Dispersion
Cold Brew CoffeeTubular Injury MarkersBefore cold brew (cystatin C)0.82 mg/LStandard Deviation 0.18
Cold Brew CoffeeTubular Injury MarkersAfter cold brew (cystatin C)0.84 mg/LStandard Deviation 0.19

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026